Reported about 21 hours ago
Thermo Fisher Scientific Inc. (NYSE:TMO) has received FDA approval for its Oncomine Dx Express Test, designed for the Ion Torrent Genexus Dx Integrated Sequencer. This test serves as both an in vitro diagnostic and a companion diagnostic for Dizal’s ZEGFROVY, a targeted therapy for non-small cell lung cancer patients with specific mutations. Capable of detecting mutations across 46 genes, this rapid next-generation sequencing technology can provide vital genomic results in as little as 24 hours, enhancing timely cancer treatment opportunities.
Source: YAHOO